The Weekly Recap 8/8/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, enter strategic partnerships, receive FDA Breakthrough Device designation, and much more on the road to LSI Europe ’25 in London (September 7–11).

BMI OrganBank

Secured FDA Breakthrough Device designation for its novel room temperature machine perfusion (RTMP) platform for kidney preservation. The designation supports upcoming clinical studies and highlights the potential to improve transplant outcomes and reduce waitlist times.

Cern

Formed a strategic partnership with Elmstead Partners, bringing capital and life sciences expertise to support Cern’s women’s health innovation. The company’s microbicidal light-based device for treating both yeast and bacterial vaginosis is now in human clinical trials in the U.S.

CorNeat Vision

Appointed Tzvika (Mike) Fisher as Chief Operations Officer to support operational scaling and global growth. His experience in strategic execution and complex production environments will help advance CorNeat Vision’s portfolio of ophthalmic devices addressing cornea, glaucoma, and ocular surface conditions.

FeelTect

Successfully completed ISO 13485 re-certification, reinforcing FeelTect’s commitment to quality and regulatory excellence. The milestone supports continued development of Tight Alright, the company’s connected-health device for improving compression therapy in venous leg ulcer care.

Immersive Touch

Appointed Ben Burnham as Chief Executive Officer, bringing over two decades of leadership experience across craniofacial, ENT, neurosurgery, and orthopedic medtech. His appointment comes at a key inflection point as ImmersiveTouch accelerates the adoption of its VR-based surgical planning platform and expands access to advanced visualization technologies.

Keyron

Appointed Christopher Rowland as Board Chair, Dr. David Feigal as Head of Regulatory Affairs, and Joyce Peetermans as Acting CTO to strengthen leadership ahead of clinical trials. The additions bring decades of expertise in endoscopic innovation, FDA engagement, and medtech commercialization as Keyron advances its reversible, non-invasive ForePass device for obesity and diabetes.

MIMOSA Diagnostics

Received a follow-on investment from Kindling Investment Partners to support its multimodal point-of-care diagnostic platform. MIMOSA’s AI-powered multimodal imaging technology is designed to improve diagnostic accuracy across all skin tones, addressing critical equity gaps in conditions like diabetic foot ulcers.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-8825-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more